Evidence map›Paper›PMID 25173705›Full record

ArticleNature methods2014

SeqControl: process control for DNA sequencing.

Lauren C Chong, Marco A Albuquerque, Nicholas J Harding, Cristian Caloian, Michelle Chan-Seng-Yue, Richard de Borja, Michael Fraser, Robert E Denroche, Timothy A Beck, Theodorus van der Kwast and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature methods, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lauren C ChongInformatics &Biocomputing Platform, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Marco A AlbuquerqueInformatics &Biocomputing Platform, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Nicholas J HardingInformatics &Biocomputing Platform, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Cristian CaloianInformatics &Biocomputing Platform, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Michelle Chan-Seng-YueInformatics &Biocomputing Platform, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Richard de BorjaInformatics &Biocomputing Platform, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Michael FraserDepartment of Pathology, University Health Network, Toronto, Ontario, Canada.
Robert E DenrocheInformatics &Biocomputing Platform, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Timothy A BeckInformatics &Biocomputing Platform, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.ORCID 0000000301453557
Theodorus van der KwastDepartment of Pathology, University Health Network, Toronto, Ontario, Canada.
Robert G Bristow1] Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada. [2] Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
John D McPherson1] Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. [2] Genomics Platform, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Paul C Boutros1] Informatics &Biocomputing Platform, Ontario Institute for Cancer Research, Toronto, Ontario, Canada. [2] Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. [3] Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.ORCID 0000000305537520

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As high-throughput sequencing continues to increase in speed and throughput, routine clinical and industrial application draws closer. These 'production' settings will require enhanced quality monitoring and quality control to optimize output and reduce costs. We developed SeqControl, a framework for predicting sequencing quality and coverage using a set of 15 metrics describing overall coverage, coverage distribution, basewise coverage and basewise quality. Using whole-genome sequences of 27 prostate cancers and 26 normal references, we derived multivariate models that predict sequencing quality and depth. SeqControl robustly predicted how much sequencing was required to reach a given coverage depth (area under the curve (AUC) = 0.993), accurately classified clinically relevant formalin-fixed, paraffin-embedded samples, and made predictions from as little as one-eighth of a sequencing lane (AUC = 0.967). These techniques can be immediately incorporated into existing sequencing pipelines to monitor data quality in real time. SeqControl is available at http://labs.oicr.on.ca/Boutros-lab/software/SeqControl/.

Indexed as

AlgorithmsArea Under CurveComputational BiologyGenomeGenotypeHumansLinear ModelsMaleMultivariate AnalysisProstatic NeoplasmsQuality ControlSequence Analysis, DNASoftware

Identifiers

PMID25173705

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.